Talis Biomedical Corporation
TLIS · OTC
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | -51.7% | 98.7% | – |
| Cost of Goods Sold | $0 | $0 | $1 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | $0 |
| % Margin | – | -267.1% | -311.9% | 92.1% |
| R&D Expenses | $2 | $3 | $8 | $8 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $8 | $6 | $6 | $9 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$1 | $0 | $0 | $0 |
| Operating Expenses | $8 | $9 | $14 | $17 |
| Operating Income | -$10 | -$9 | -$15 | -$17 |
| % Margin | – | -12,528.8% | -9,602.6% | -22,330.3% |
| Other Income/Exp. Net | $1 | -$4 | $1 | $1 |
| Pre-Tax Income | -$9 | -$13 | -$13 | -$16 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$9 | -$13 | -$13 | -$16 |
| % Margin | – | -17,856.2% | -8,913.9% | -20,634.2% |
| EPS | -4.86 | -7.15 | -7.4 | -8.62 |
| % Growth | 32% | 3.4% | 14.2% | – |
| EPS Diluted | -4.86 | -7.15 | -7.4 | -8.62 |
| Weighted Avg Shares Out | 2 | 2 | 2 | 2 |
| Weighted Avg Shares Out Dil | 2 | 2 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $1 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $1 |
| EBITDA | -$9 | -$14 | -$14 | -$16 |
| % Margin | – | -18,979.5% | -9,462.9% | -21,548.7% |